About SKB BIO-B Company

Sichuan Colunbotai Biomedical Co., Ltd. (hereinafter referred to as “Colunbotai” or the “Company”) is a biomedical company focusing on R&D, manufacturing and commercialization of innovative drugs. Since its establishment in 2016, it has always been committed to solving the medical needs of China and the world at large. With integrated drug development capabilities and a complete management mechanism covering all key business functions, Colunbott is committed to developing differentiated treatments internally to support the improvement of existing healthcare standards. As a pioneer and one of the leading developers of antibody drug conjugates (ADCs), Columbotai has accumulated more than ten years of experience in ADC development, and is one of the first biopharmaceutical companies in China and one of the few biopharmaceutical companies in the world to establish an integrated ADC R&D platform, OptiDC. The company uses a systematic, indication-oriented approach to address the world's most common or difficult to treat cancers and other diseases and conditions with large numbers of patients and unmet medical needs. After many years, the company has established integrated capabilities covering all major drug development functions, including R&D, production, quality control and commercialization, and can strategically rapidly advance 33 differentiated and clinically valuable asset pipelines, 14 of which are in the clinical stage. With the support of three self-developed technology platforms, Colombotech already has proprietary technology in ADC, macromolecules (monoclonal antibodies (monoclonal antibodies), bispecific antibodies (double antibodies), and small molecule drugs, etc., and has been verified by the company's many clinical-stage drug candidates. The company has built a strong pipeline that is diverse in terms of drug modality, mechanism and coverage of indications, and can exert synergistic effects. The controlling shareholder Colon Pharmaceutical's decades of experience, industry relationships and extensive network have created favorable conditions for Colon Botai to expand its commercial infrastructure and market channels. At the same time, the clinical value of the pipeline and drug development capabilities of Colombotech have also been recognized by strategic partners around the world. To date, the company has signed nine external licensing agreements, including three licensing and cooperation agreements with MerckSharp & Dohmellc (together with its affiliate, “MSD”) to develop up to nine ADC assets for cancer treatment. The total amount of upfront and milestone payments amounted to $11.8 billion. These strategic partnerships not only prove the company's R&D and business development capabilities, but are also a key driver for continuous innovation, building global influence and long-term growth. Looking forward to the future, Columbotai will strive to promote pipeline commercialization and enhance integrated drug development capabilities, continue to lead the development and clinical activities of drug candidates, and strive to optimize R&D platforms and develop new technologies to support the research and development of innovative drugs. Columbite will also continue to expand cGMP production and quality control facilities and enhance internal commercialization functions to support future pipeline assets and achieve the goal of becoming a leading global biopharmaceutical company.